View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
December 5, 2018updated 12 Jul 2022 1:09pm

Grail to begin trial of blood test for early cancer detection

Grail is set to start a new trial next year to assess the ability of an investigational blood test to detect a number of cancer types.

Grail is set to start a new trial next year to assess the ability of an investigational blood test to detect a number of cancer types.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

SUMMIT is a prospective observational, longitudinal, cohort study that aims to enrol around 50,000 men and women aged 50 to 77 years who do not have a cancer diagnosis at the time of recruitment.

Nearly half of participants will be at high risk of developing lung and other cancers because of their significant smoking history.

Healthcare company Grail is expected to use next-generation sequencing (NGS) technology as part of the trial.

“SUMMIT will support the development of our blood test for the early detection of multiple cancer types in a diverse population.”

It plans to carry out the trial in the UK in collaboration with University College London (UCL) and the university’s National Health Service (NHS) Foundation Trust (UCLH).

US-based non-profit organisation Lung Cancer Alliance (LCA) will provide guidance on the study design of SUMMIT.

Grail Clinical Development vice-president Anne-Renee Hartman said: “The SUMMIT study will support the development of our blood test for the early detection of multiple cancer types in a diverse population.”

SUMMIT aims to help UCL and UCLH achieve their goal of evaluating the feasibility of implementing lung cancer screening in the UK.

Participants are also expected to have the opportunity to undergo lung cancer screening with low dose computed tomography (LDCT) and will have support for smoking cessation through the NHS in the UK.

LDCT is recommended by the US Preventive Services Task Force (USPSTF) for use in people who are at high risk for lung cancer due to current or former smoking habit.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena